drugset / Trial / NCT05031026

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

NCT05031026 ↗

Phase 4 Active not recruiting 60 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

Timeline

Start
2022-03-15
Primary completion
2025-12-15
Completion
2026-02-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified — —

Indications

No indication recorded.